Amgen Inc (AMGN) Stock Analysis and Metrics

Amgen

NASDAQ: AMGN

$366.36 ▼ -5.22 (-1.40%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap195.12 Bn

P/E25.02

P/S5.24

Div. Yield0.03

ROIC (Qtr)0.00

Total Debt (Qtr)57.32 Bn

Revenue Growth (1y) (Qtr)5.76

Add ratio to table…

About

Amgen Inc. discovers, develops, manufactures and delivers innovative medicines to treat serious diseases, operating as a leading independent biotechnology company with a presence in approximately 100 countries worldwide. The company focuses on areas of high unmet medical need and leverages its scientific expertise to improve patient outcomes while reducing the societal burden of illness.

Amgen generates revenue primarily from the sale of its therapeutic medicines across oncology, inflammation, bone health, cardiovascular and other therapeutic areas. Its product portfolio includes marketed drugs such as Prolia, XGEVA, Otezla, ENBREL, EVENITY, Repatha, and many others, which are distributed through a global network. In the United States, substantially all sales are made to pharmaceutical wholesale distributors, while outside the United States the company sells to healthcare providers and/or local distributors depending on country practices.

The company operates through the following segments.

• The human therapeutics segment encompasses the discovery, development, manufacturing and commercialization of innovative medicines for a wide range of serious diseases, including oncology, inflammation, bone health, cardiovascular and metabolic disorders, with a robust pipeline of potential first in class candidates and a global presence in approximately 100 countries.

Amgen is one of the world's leading independent biotechnology companies, competing against large pharmaceutical firms and emerging biotech rivals in its therapeutic areas. In its major product lines, Amgen faces competition from biosimilars and generic alternatives, as well as branded rivals such as Novartis’ LEQVIO and Regeneron’s PRALUENT for Repatha, and AbbVie’s Skyrizi and Taltz for Otezla. The company’s competitive advantages stem from its extensive scientific expertise, deep pipeline of potential first in class medicines, global manufacturing capabilities, and strong brand reputation for reliability and safety.

Amgen’s customer base consists principally of pharmaceutical wholesale distributors, hospitals, pharmacies and other healthcare providers worldwide. In the United States, a significant portion of sales is made to three large wholesalers: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each of which accounted for more than 10% of total revenues in recent years. Outside the United States, the company sells directly to healthcare providers or through local distributors depending on each country’s distribution practices.

Investment Thesis

▲ Bull case

Amgen's strategic diversification across multiple high-growth therapeutic areas is creating resilient revenue streams that are offsetting legacy product declines, with the six key growth drivers generating $5.6 billion in Q1 sales (70% of total product sales) and growing 24% year-over-year, driven by robust performance in Repatha (34% growth to $876 million), Evenity (27% growth to $562 million), and the rare disease portfolio (25% growth to $1.2 billion), which includes explosive UPLIZNA growth of 188% to $262 million, demonstrating the company's ability to successfully launch and scale new indications in underserved markets with significant unmet need, such as the over 90% of 2 million high fracture risk women in the U.S. remaining untreated for osteoporosis, positioning Evenity for substantial market expansion beyond its current 65% U.S. market share in the bone builder category. The Meritide (maridebart cafraglutide) pipeline represents a transformative opportunity in the obesity and type 2 diabetes market, with its unique antibody-peptide conjugate design enabling monthly or less frequent dosing, which addresses critical treatment burden and persistence barriers of existing GLP-1 therapies, supported by positive Phase I data showing three-step dose escalation further reduces nausea and vomiting rates, and the initiation of two Phase III maintenance studies and a switch study evaluating conversion from weekly injectables to every eight or twelve week dosing, which could capture significant market share from patients dissatisfied with current injection frequency or side effects, while Amgen's AI-driven R&D advancements—including 50% faster antibody lead optimization and up to threefold improvements in clinical trial enrollment—are accelerating pipeline execution and de-risking late-stage programs like Olpasiran, which targets the genetically defined Lp(a) risk factor with >95% reduction potential and quarterly dosing, presenting a first-in-class opportunity in cardiovascular prevention where background therapies like statins and PCSK9 inhibitors have no meaningful impact on Lp(a) levels. Amgen's biosimilars portfolio is achieving sustainable, low-cost growth with $835 million in Q1 sales (14% year-over-year increase) and cumulative sales surpassing $14 billion since 2018, driven by PABLUE's $280 million in Q1 sales as a biosimilar to EYLEA, which benefits from ready-to-use prefilled syringe adoption among retina specialists and Amgen's reliable supply chain, while the company's $300 million additional investment in Puerto Rico manufacturing—part of a broader $2.6 billion 2026 capital expenditure plan—strengthens U.S.-based biomanufacturing capacity, supports Meritide launch readiness, and enhances supply chain resilience against geopolitical risks, positioning Amgen to leverage its scale and operational efficiency to maintain competitive pricing and margin stability despite ongoing cost of sales pressures from higher profit share and royalty expenses.

Amgen's strategic diversification across multiple high-growth therapeutic areas is creating resilient revenue streams that are offsetting legacy product declines, with the six key growth drivers generating $5.6 billion in Q1 sales (70% of total product sales) and growing 24% year-over-year, driven by robust performance in Repatha (34% growth to $876 million), Evenity (27% growth to $562 million), and the rare disease portfolio (25% growth to $1.2 billion), which includes explosive UPLIZNA growth of 188% to $262 million, demonstrating the company's ability to successfully launch and scale new indications in underserved markets with significant unmet need, such as the over 90% of 2 million high fracture risk women in the U.S. remaining untreated for osteoporosis, positioning Evenity for substantial market expansion beyond its current 65% U.S. market share in the bone builder category. The Meritide (maridebart cafraglutide) pipeline represents a transformative opportunity in the obesity and type 2 diabetes market, with its unique antibody-peptide conjugate design enabling monthly or less frequent dosing, which addresses critical treatment burden and persistence barriers of existing GLP-1 therapies, supported by positive Phase I data showing three-step dose escalation further reduces nausea and vomiting rates, and the initiation of two Phase III maintenance studies and a switch study evaluating conversion from weekly injectables to every eight or twelve week dosing, which could capture significant market share from patients dissatisfied with current injection frequency or side effects, while Amgen's AI-driven R&D advancements—including 50% faster antibody lead optimization and up to threefold improvements in clinical trial enrollment—are accelerating pipeline execution and de-risking late-stage programs like Olpasiran, which targets the genetically defined Lp(a) risk factor with >95% reduction potential and quarterly dosing, presenting a first-in-class opportunity in cardiovascular prevention where background therapies like statins and PCSK9 inhibitors have no meaningful impact on Lp(a) levels. Amgen's biosimilars portfolio is achieving sustainable, low-cost growth with $835 million in Q1 sales (14% year-over-year increase) and cumulative sales surpassing $14 billion since 2018, driven by PABLUE's $280 million in Q1 sales as a biosimilar to EYLEA, which benefits from ready-to-use prefilled syringe adoption among retina specialists and Amgen's reliable supply chain, while the company's $300 million additional investment in Puerto Rico manufacturing—part of a broader $2.6 billion 2026 capital expenditure plan—strengthens U.S.-based biomanufacturing capacity, supports Meritide launch readiness, and enhances supply chain resilience against geopolitical risks, positioning Amgen to leverage its scale and operational efficiency to maintain competitive pricing and margin stability despite ongoing cost of sales pressures from higher profit share and royalty expenses.

▼ Bear case

Amgen faces accelerating structural decline in its established products, particularly Prolia and XGEVA, which combined for $1.1 billion in Q1 sales but declined 32% year-over-year due to biosimilar competition, with management explicitly warning of "accelerated sales erosion over the remainder of 2026 driven by increased competition from multiple biosimilars," and this erosion is compounded by the ongoing decline in Ultra-Rare products (down 45% to $98 million) and Enbrel (down 37% to $320 million), creating a significant headwind that the high-growth portfolio may not fully offset, especially as biosimilar competition intensifies across multiple legacy franchises simultaneously, threatening to undermine the company's ability to maintain top-line growth despite diversification efforts. Tavneos remains under severe regulatory threat, with the FDA proposing to withdraw approval due to lack of proven effectiveness and false statements in the original application, compounded by real-world safety concerns including approximately 20 deaths linked to serious liver dysfunction in Japan and 76 U.S. cases of drug-induced liver injury with causal evidence, including eight deaths, which Amgen is addressing through an independent Duke Clinical Research Institute data review, but the outcome remains highly uncertain, and even if Tavneos retains approval, the ongoing liver safety signal and restrictive prescribing environment in key markets like Japan—where about 8,503 patients have been treated since 2022—will severely limit its commercial potential and erode confidence in Amgen's recent acquisition integration capabilities following the ChemoCentryx purchase. Amgen's financial outlook is exposed to material tax risks from the IRS draft Notice of Proposed Adjustment (NOPA) for tax years 2016–2018, which asserts significant adjustments related to profit allocation between the U.S. and Puerto Rico, and if sustained in full, could have a material impact on financial statements, with CFO Griffith explicitly warning of this risk during the earnings call, and while Amgen disputes the NOPA's methodology, the ongoing audit and potential for adverse resolution introduce substantial uncertainty to the company's effective tax rate guidance of 15%–16.5%, especially given the history of prior IRS disputes (2010–2015) currently pending in tax court, which could result in unexpected tax liabilities that undermine the projected non-GAAP EPS guidance of $21.70–$23.10 and free cash flow generation despite strong operational performance.

Amgen faces accelerating structural decline in its established products, particularly Prolia and XGEVA, which combined for $1.1 billion in Q1 sales but declined 32% year-over-year due to biosimilar competition, with management explicitly warning of "accelerated sales erosion over the remainder of 2026 driven by increased competition from multiple biosimilars," and this erosion is compounded by the ongoing decline in Ultra-Rare products (down 45% to $98 million) and Enbrel (down 37% to $320 million), creating a significant headwind that the high-growth portfolio may not fully offset, especially as biosimilar competition intensifies across multiple legacy franchises simultaneously, threatening to undermine the company's ability to maintain top-line growth despite diversification efforts. Tavneos remains under severe regulatory threat, with the FDA proposing to withdraw approval due to lack of proven effectiveness and false statements in the original application, compounded by real-world safety concerns including approximately 20 deaths linked to serious liver dysfunction in Japan and 76 U.S. cases of drug-induced liver injury with causal evidence, including eight deaths, which Amgen is addressing through an independent Duke Clinical Research Institute data review, but the outcome remains highly uncertain, and even if Tavneos retains approval, the ongoing liver safety signal and restrictive prescribing environment in key markets like Japan—where about 8,503 patients have been treated since 2022—will severely limit its commercial potential and erode confidence in Amgen's recent acquisition integration capabilities following the ChemoCentryx purchase. Amgen's financial outlook is exposed to material tax risks from the IRS draft Notice of Proposed Adjustment (NOPA) for tax years 2016–2018, which asserts significant adjustments related to profit allocation between the U.S. and Puerto Rico, and if sustained in full, could have a material impact on financial statements, with CFO Griffith explicitly warning of this risk during the earnings call, and while Amgen disputes the NOPA's methodology, the ongoing audit and potential for adverse resolution introduce substantial uncertainty to the company's effective tax rate guidance of 15%–16.5%, especially given the history of prior IRS disputes (2010–2015) currently pending in tax court, which could result in unexpected tax liabilities that undermine the projected non-GAAP EPS guidance of $21.70–$23.10 and free cash flow generation despite strong operational performance.

Peer Comparison

Companies in the Drug Manufacturers - General

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LLY	ELI LILLY & Co	1,066.16 Bn	42.18	14.76	43.37 Bn
2	JNJ	Johnson & Johnson	611.69 Bn	29.07	6.35	54.99 Bn
3	ABBV	AbbVie Inc.	444.34 Bn	122.04	7.07	64.53 Bn
4	AZN	Astrazeneca Plc	284.94 Bn	23.78	2,793.52	-24.45 Bn
5	MRK	Merck & Co., Inc.	224.23 Bn	25.00	3.41	49.12 Bn
6	AMGN	Amgen Inc	195.12 Bn	25.02	5.24	57.32 Bn
7	GILD	Gilead Sciences, Inc.	156.45 Bn	16.36	5.26	22.17 Bn
8	PFE	Pfizer Inc	136.01 Bn	11,334.57	5.56	64.46 Bn

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password